AU2022239497A1 - Compositions and methods for treating neurologic diseases - Google Patents

Compositions and methods for treating neurologic diseases Download PDF

Info

Publication number
AU2022239497A1
AU2022239497A1 AU2022239497A AU2022239497A AU2022239497A1 AU 2022239497 A1 AU2022239497 A1 AU 2022239497A1 AU 2022239497 A AU2022239497 A AU 2022239497A AU 2022239497 A AU2022239497 A AU 2022239497A AU 2022239497 A1 AU2022239497 A1 AU 2022239497A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
group
pharmaceutically acceptable
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022239497A
Other languages
English (en)
Inventor
Anthony Caggiano
Susan M. Catalano
Mary HAMBY
Nicholas IZZO
Gary C. Look
Gilbert M. Rishton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognition Therapeutics Inc
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of AU2022239497A1 publication Critical patent/AU2022239497A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022239497A 2021-03-19 2022-03-17 Compositions and methods for treating neurologic diseases Pending AU2022239497A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163546P 2021-03-19 2021-03-19
US63/163,546 2021-03-19
PCT/US2022/020687 WO2022197885A1 (en) 2021-03-19 2022-03-17 Compositions and methods for treating neurologic diseases

Publications (1)

Publication Number Publication Date
AU2022239497A1 true AU2022239497A1 (en) 2023-09-21

Family

ID=83320987

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022239497A Pending AU2022239497A1 (en) 2021-03-19 2022-03-17 Compositions and methods for treating neurologic diseases

Country Status (10)

Country Link
US (2) US20240165077A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024510249A (cg-RX-API-DMAC7.html)
KR (1) KR20230159546A (cg-RX-API-DMAC7.html)
CN (1) CN117355525A (cg-RX-API-DMAC7.html)
AU (1) AU2022239497A1 (cg-RX-API-DMAC7.html)
CA (1) CA3212092A1 (cg-RX-API-DMAC7.html)
IL (1) IL306063A (cg-RX-API-DMAC7.html)
MX (1) MX2023010831A (cg-RX-API-DMAC7.html)
WO (1) WO2022197885A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026064542A1 (en) * 2024-09-18 2026-03-26 Cognition Therapeutics, Inc. 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms
WO2026119142A1 (zh) * 2024-12-03 2026-06-11 浙江径科医药有限公司 一种氘代异吲哚啉化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US20200000822A1 (en) * 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
JP2022537581A (ja) * 2019-06-21 2022-08-26 クラリス コーポレーション Ppm1阻害剤およびその使用方法
CN110283082A (zh) * 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法

Also Published As

Publication number Publication date
CN117355525A (zh) 2024-01-05
EP4308565A4 (en) 2025-01-01
WO2022197885A1 (en) 2022-09-22
KR20230159546A (ko) 2023-11-21
MX2023010831A (es) 2023-09-27
US20240165077A1 (en) 2024-05-23
US20260166006A1 (en) 2026-06-18
IL306063A (en) 2023-11-01
CA3212092A1 (en) 2022-09-22
EP4308565A1 (en) 2024-01-24
JP2024510249A (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
US20240165077A1 (en) Compositions and methods for treating neurologic diseases
US11981636B2 (en) Compositions for treating neurodegenerative diseases
US20240009168A1 (en) Compositions for treating dry age-related macular degeneration (amd)
JP5693970B2 (ja) ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤
JP7596296B2 (ja) 炎症性障害を治療するための化合物および方法
CN114599371A (zh) 作为癌症靶向药物载体的磷脂醚缀合物
KR20110021946A (ko) 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도
WO2025122753A2 (en) Compositions and methods for the treatment of niemann-pick disease
US20240246911A1 (en) Novel tryptamines and methods of treating mood disorders
WO2026030341A1 (en) Zervimesine for treating neurodegenerative disease
RU2792562C2 (ru) Композиции для лечения нейродегенеративных заболеваний
CA3061787C (en) Compositions for treating neurodegenerative diseases
HK40056643A (en) Compounds and methods for treating inflammatory disorders
KR20260002803A (ko) 치료적 사용을 위한 암브록솔의 변형된 형태